Equity Overview
Price & Market Data
Price: $3.71
Daily Change: +$0.01 / 0.27%
Range: $3.52 - $3.78
Market Cap: $324,023,232
Volume: 1,100,737
Performance Metrics
1 Week: 13.11%
1 Month: 23.67%
3 Months: 10.42%
6 Months: -47.60%
1 Year: -46.00%
YTD: -33.03%
Company Details
Employees: 59
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.